Teva sells off the rest of its women’s health assets in $2.5B deal

After the company divested its Paragard intrauterine device assets for $1.1 billion in cash last week, Teva Pharmaceuticals (NYSE:TEVA) announced today that it plans to sell off the rest of its global women’s health biz.

Combined with proceeds from its Paragard deal, the sale of Teva’s global women’s health assets will total $2.48 billion, the company reported. Teva said it plans to use the funds to repay term loan debt.

Get the full story at our sister site, Drug Delivery Business News.

The post Teva sells off the rest of its women’s health assets in $2.5B deal appeared first on MassDevice.

from MassDevice http://ift.tt/2xseKA3